Pharmacyte Biotech Inc(OTCMKTS:PMCB) which owns the exclusive worldwide rights to develop treatments for all types of solid cancerous tumors using its signature Cell-in-a-Box technology combined with low doses of the chemotherapy drug ifosfamide is directly aiming at the problem patients with advanced pancreatic cancer face, an inoperable tumor. It is this treatment (Cell-in-a-Box/ifosfamide) that was just awarded with the U.S. Food and Drug Administration’s (FDA) Orphan Drug designation. Armed with the FDA’s Orphan Drug designation, PharmaCyte can now take direct aim at becoming the treatment of choice for advanced pancreatic cancer.
Using Cell-in-Box allows PharmaCyte Biotech to use only one-third the normal dose of ifosfamide normally given to fight cancer. The proximity of the activation to the tumor site lessens the amount of ifosfamide required and, in turn, virtually eliminates the side effects usually seen with chemotherapy. The unique properties of the Cell-in-a-Box capsules cover the gamut of durability and provide the ability to be shipped anywhere in the world to be used when needed. The capsules and the cells within them have the ability to be frozen and stored for, at least, five years and can then be thawed for use to fight cancer in humans. These capsules are designed in such a way that it completely protects the cells from any attack by the immune system. No other encapsulation technology in the world has these properties.
Pancreatic cancer is a notoriously stubborn disease that hides behind a fortified wall of tissue while becoming entangled with blood vessels and organs. In fact, pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. and has the highest mortality rate amongst major cancers with 74 percent of patients dying within the first 12 months of diagnosis.